Filing Flows › Bioventus (BVS) › Guidance & outlook
Bioventus (BVS) guidance and outlook
Bioventus (BVS) updated its guidance on Nov 2, 2026: EPS $0.75–$0.79 for the year ending Dec 31, 2026; Revenue $590M–$595M for the year ending Dec 31, 2026; Revenue +4% to +5% for the year ending Dec 31, 2026. Bioventus' 10-Q filed Nov 2, 2026 makes 8 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| EPS | the year ending Dec 31, 2026 | $0.75–$0.79 | new |
| Revenue | the year ending Dec 31, 2026 | $590M–$595M | new |
| Revenue | the year ending Dec 31, 2026 | +4% to +5% | new |
From the earnings release filed Nov 2, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 2, 2026
- We plan to expand our U.S. clinical fracture care indications to address the healing of additional fresh fractures, especially for high-risk patients.
- We expect these needs to continue as we develop and market new products and further expand into international markets.
- This availability, combined with our existing cash balances and expected cash flows from operations, provides us with sufficient liquidity to meet our near-term obligations and supports our ongoing operations for the next twelve months.
- To the extent additional capital is required, we anticipate that we will seek funding through a combination of equity financings, the incurrence of additional indebtedness, or other strategic sources of capital.
- We cannot be certain that additional funding will be available on acceptable terms, or at all.
- We expect the amount of the cash payments required to be made under the TRA will be significant.
- To the extent that we are unable to make payments under the TRA for any reason, such payments generally will be deferred and will accrue interest until paid; provided, however, that nonpayment for a specified period may constitute a material breach of a material obligation under the TRA and therefore accelerate payments due under the TRA.
- We do not expect any of these covenants or restrictions to affect or limit our ability to conduct business in the ordinary course.
Bioventus' latest quarter
Bioventus, Q3 2026: revenue $142M (+3% year over year), operating margin 6.8%, net earnings $6.0M, operating cash flow $20.7M. The chart follows the revenue to costs, profit and cash.
Questions
Did Bioventus raise or lower its guidance?
Bioventus (BVS) updated its guidance on Nov 2, 2026: EPS $0.75–$0.79 for the year ending Dec 31, 2026; Revenue $590M–$595M for the year ending Dec 31, 2026; Revenue +4% to +5% for the year ending Dec 31, 2026.
What does Bioventus expect?
We plan to expand our U.S. clinical fracture care indications to address the healing of additional fresh fractures, especially for high-risk patients. We expect these needs to continue as we develop and market new products and further expand into international markets. This availability, combined with our existing cash balances and expected cash flows from operations, provides us with sufficient liquidity to meet our near-term obligations and supports our ongoing operations for the next twelve months.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.